Cargando…
Identification of anticancer OATP2B1 substrates by an in vitro triple-fluorescence-based cytotoxicity screen
Membrane transporters play an important role in the absorption, distribution, metabolism and excretion of drugs. The cellular accumulation of many drugs is the result of the net function of efflux and influx transporters. Efflux transporters such as P-glycoprotein/ABCB1 have been shown to confer mul...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510822/ https://www.ncbi.nlm.nih.gov/pubmed/30863990 http://dx.doi.org/10.1007/s00204-019-02417-6 |
_version_ | 1783417475504799744 |
---|---|
author | Windt, Tímea Tóth, Szilárd Patik, Izabel Sessler, Judit Kucsma, Nóra Szepesi, Áron Zdrazil, Barbara Özvegy-Laczka, Csilla Szakács, Gergely |
author_facet | Windt, Tímea Tóth, Szilárd Patik, Izabel Sessler, Judit Kucsma, Nóra Szepesi, Áron Zdrazil, Barbara Özvegy-Laczka, Csilla Szakács, Gergely |
author_sort | Windt, Tímea |
collection | PubMed |
description | Membrane transporters play an important role in the absorption, distribution, metabolism and excretion of drugs. The cellular accumulation of many drugs is the result of the net function of efflux and influx transporters. Efflux transporters such as P-glycoprotein/ABCB1 have been shown to confer multidrug resistance in cancer. Although expression of uptake transporters has been confirmed in cancer cells, their role in chemotherapy response has not been systematically investigated. In the present study we have adapted a fluorescence-based cytotoxic assay to characterize the influence of key drug-transporters on the toxicity of approved anticancer drugs. Co-cultures of fluorescently labeled parental and transporter-expressing cells (expressing ABCB1, ABCG2 or OATP2B1) were screened against 101 FDA-approved anticancer drugs, using a novel, automated, triple fluorescence-based cytotoxicity assay. By measuring the survival of parental and transporter-expressing cells in co-cultures, we identify those FDA-approved anticancer drugs, whose toxicity is influenced by ABCB1, ABCG2 or OATP2B1. In addition to confirming known substrates of ABCB1 and ABCG2, the fluorescence-based cytotoxicity assays identified anticancer agents whose toxicity was increased in OATP2B1 expressing cells. Interaction of these compounds with OATP2B1 was verified in dedicated transport assays using cell-impermeant fluorescent substrates. Understanding drug-transporter interactions is needed to increase the efficacy of chemotherapeutic agents. Our results highlight the potential of the fluorescence-based HT screening system for identifying transporter substrates, opening the way for the design of therapeutic approaches based on the inhibition or even the exploitation of transporters in cancer cells. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00204-019-02417-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6510822 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-65108222019-05-28 Identification of anticancer OATP2B1 substrates by an in vitro triple-fluorescence-based cytotoxicity screen Windt, Tímea Tóth, Szilárd Patik, Izabel Sessler, Judit Kucsma, Nóra Szepesi, Áron Zdrazil, Barbara Özvegy-Laczka, Csilla Szakács, Gergely Arch Toxicol In Vitro Systems Membrane transporters play an important role in the absorption, distribution, metabolism and excretion of drugs. The cellular accumulation of many drugs is the result of the net function of efflux and influx transporters. Efflux transporters such as P-glycoprotein/ABCB1 have been shown to confer multidrug resistance in cancer. Although expression of uptake transporters has been confirmed in cancer cells, their role in chemotherapy response has not been systematically investigated. In the present study we have adapted a fluorescence-based cytotoxic assay to characterize the influence of key drug-transporters on the toxicity of approved anticancer drugs. Co-cultures of fluorescently labeled parental and transporter-expressing cells (expressing ABCB1, ABCG2 or OATP2B1) were screened against 101 FDA-approved anticancer drugs, using a novel, automated, triple fluorescence-based cytotoxicity assay. By measuring the survival of parental and transporter-expressing cells in co-cultures, we identify those FDA-approved anticancer drugs, whose toxicity is influenced by ABCB1, ABCG2 or OATP2B1. In addition to confirming known substrates of ABCB1 and ABCG2, the fluorescence-based cytotoxicity assays identified anticancer agents whose toxicity was increased in OATP2B1 expressing cells. Interaction of these compounds with OATP2B1 was verified in dedicated transport assays using cell-impermeant fluorescent substrates. Understanding drug-transporter interactions is needed to increase the efficacy of chemotherapeutic agents. Our results highlight the potential of the fluorescence-based HT screening system for identifying transporter substrates, opening the way for the design of therapeutic approaches based on the inhibition or even the exploitation of transporters in cancer cells. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00204-019-02417-6) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2019-03-12 2019 /pmc/articles/PMC6510822/ /pubmed/30863990 http://dx.doi.org/10.1007/s00204-019-02417-6 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | In Vitro Systems Windt, Tímea Tóth, Szilárd Patik, Izabel Sessler, Judit Kucsma, Nóra Szepesi, Áron Zdrazil, Barbara Özvegy-Laczka, Csilla Szakács, Gergely Identification of anticancer OATP2B1 substrates by an in vitro triple-fluorescence-based cytotoxicity screen |
title | Identification of anticancer OATP2B1 substrates by an in vitro triple-fluorescence-based cytotoxicity screen |
title_full | Identification of anticancer OATP2B1 substrates by an in vitro triple-fluorescence-based cytotoxicity screen |
title_fullStr | Identification of anticancer OATP2B1 substrates by an in vitro triple-fluorescence-based cytotoxicity screen |
title_full_unstemmed | Identification of anticancer OATP2B1 substrates by an in vitro triple-fluorescence-based cytotoxicity screen |
title_short | Identification of anticancer OATP2B1 substrates by an in vitro triple-fluorescence-based cytotoxicity screen |
title_sort | identification of anticancer oatp2b1 substrates by an in vitro triple-fluorescence-based cytotoxicity screen |
topic | In Vitro Systems |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510822/ https://www.ncbi.nlm.nih.gov/pubmed/30863990 http://dx.doi.org/10.1007/s00204-019-02417-6 |
work_keys_str_mv | AT windttimea identificationofanticanceroatp2b1substratesbyaninvitrotriplefluorescencebasedcytotoxicityscreen AT tothszilard identificationofanticanceroatp2b1substratesbyaninvitrotriplefluorescencebasedcytotoxicityscreen AT patikizabel identificationofanticanceroatp2b1substratesbyaninvitrotriplefluorescencebasedcytotoxicityscreen AT sesslerjudit identificationofanticanceroatp2b1substratesbyaninvitrotriplefluorescencebasedcytotoxicityscreen AT kucsmanora identificationofanticanceroatp2b1substratesbyaninvitrotriplefluorescencebasedcytotoxicityscreen AT szepesiaron identificationofanticanceroatp2b1substratesbyaninvitrotriplefluorescencebasedcytotoxicityscreen AT zdrazilbarbara identificationofanticanceroatp2b1substratesbyaninvitrotriplefluorescencebasedcytotoxicityscreen AT ozvegylaczkacsilla identificationofanticanceroatp2b1substratesbyaninvitrotriplefluorescencebasedcytotoxicityscreen AT szakacsgergely identificationofanticanceroatp2b1substratesbyaninvitrotriplefluorescencebasedcytotoxicityscreen |